Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2023 Earnings Results

Crinetics Pharmaceuticals Misses on EPS, Stock Down 3.89%

The earnings report indicates that Crinetics Pharmaceuticals is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 3.89% in response to the disappointing results and lack of guidance. Investors may be cautious as the company navigates its current situation without clear direction for the future.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.94	N/A	-11.24%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about current market conditions and their impact on performance. They are focusing on internal improvements but did not provide specific guidance.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing efforts to improve operational efficiency.

No specific updates on product pipeline were provided.

Crinetics Pharmaceuticals Misses on EPS, Stock Down 3.89%

Key numbers

Management commentary

Crinetics Pharmaceuticals, Inc.

More earnings this week

Crinetics Pharmaceuticals Misses on EPS, Stock Down 3.89%

Key numbers

Management commentary